Nanobiotix (NASDAQ:NBTX), a late-clinical stage biotechnology company, announced the presentation of new preclinical data today at the 2026 Annual Meeting of the American Association for Cancer Research (AACR).
The findings highlight the ability of the company’s Nanoprimer platform to optimize the systemic delivery of recombinant DNA encapsulated in lipid nanoparticles (LNP-DNA).
One of the primary challenges in the development of LNP-based therapies is the rapid clearance of these particles by the liver, which acts as a biological filter.
This "liver trap" not only reduces the amount of therapy available to reach intended targets elsewhere in the body but also often triggers localized hepatic toxicity and acute inflammatory responses via the cGAS-STING signaling pathway.
In the mouse model studies presented at AACR, Nanobiotix demonstrated that administering the Nanoprimer intravenously shortly before the LNP-DNA treatment effectively "primed" the system.
The Nanoprimer transiently occupies the hepatic clearance pathways, allowing the subsequent LNP-DNA therapy to remain in circulation for a longer duration.
This sequencing resulted in a significant increase in systemic bioavailability and a simultaneous reduction in liver uptake.
Beyond improving the reach of the therapy, the data showed that the Nanoprimer attenuated the inflammatory signaling typically associated with LNP administration.
By minimizing the concentration of particles accumulating in the liver, the pre-treatment successfully reduced hepatic toxicity compared to the administration of LNP-DNA alone.
These results provide a strong foundation for the further evaluation of the Nanoprimer in sequence with advanced extrahepatic LNP systems.
Management noted that the findings support the potential for the technology to improve both the efficacy and safety of a wide range of genomic medicines.